ClinicalTrials.gg
RecruitingNCT03691883STAGE-TBUpdated Dec 27, 2024

Design of an Integrative Algorithm for Staging Tuberculosis

An observational study in Tuberculosis, sponsored by Fundació Institut Germans Trias i Pujol. Recruiting at 5 sites in Spain. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Fundació Institut Germans Trias i Pujol · Observational

How we know

From the registry’s dates

  • Started Apr 2018; still recruiting 8 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Tuberculosis with a site in Spain — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · Spain.

Started
2018
with 1 other
Observational
6 of 25
2 open now
Registered
15th of 25
by date
Lead sponsor
3 of 25
Fundació Institut Germans Trias i Pujol

Among the 25 studies in Tuberculosis with a site in Spain, this one is one of 2 that started in 2018, is one of 6 observational ones, and was the 15th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

4 of the 25 studies in Tuberculosis with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Tuberculosis with a site in Spain, or all of them as a file.
02

Study summary

Tuberculosis is a chronic infectious disease that affects 10 million people, 300 in the city of Barcelona, every year. With serious consequences at public health level, it is associated with other diseases, and generated and influenced by many social and psychological factors. This study aims to stage tuberculosis disease by an integrative approach.

Read the detailed description

Tuberculosis is a chronic infectious disease that affects 10 million people, there are 300 new cases 300 in the city of Barcelona, every year. Tuberculosis has serious consequences at public health level. It is associated with other diseases, and generated and influenced by many social and psychological factors. This study aims to stage tuberculosis disease by a novel integrative approach.

03

Conditions studied

  • Tuberculosis

Keywords

  • tuberculosis, infectious diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

TB patients which clinical management is done at the following clinical centers: Servicios Clínicos, Hospital Universitari Vall d'Hebron-Drassanes or Hospital Universitari Germans Trias i Pujol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • TB diagnosis (all forms), microbiologically confirmed (by AFB+, GenXpert+ or Culture+)
  • Clinical management of the patients being done at Servicios Clínicos, Hospital Universitari Vall d'Hebron-Drassanes or Hospital Universitari Germans Trias i Pujol.

Exclusion criteria

Exclusion Criteria:

  • Not consenting to data/samples donation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • TB patients

    TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.

06

What researchers measure

Primary outcomes

  1. Clinical changes

    Changes in clinical status

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

  2. Microbiological changes

    Changes in microbiological cultures

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

Secondary outcomes

  1. Changes in Biomarkers values

    Changes in the biomarkers along time assessed by using analyzing parameters in blood and urine samples (by ELISA and LUMINEX)

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

  2. Radiological Score Value

    Changes in the BCN-SA Radiological Score Value. This Score assesses the sum of acute and chronic findings in the chest X-ray. Per each finding, a maximum score of 8 is recorded. The total score value is calculated by adding all the individual findings score values. Higher values of total score represent a worse outcome.

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

  3. Changes in SGRQ score

    Changes in Health Quality of Life measures along time assessed by using the Saint George's Respiratory Questionnaire (SGRQ, numeric score). It measures 3 subscales (symptoms/activity/impacts) and The Total score is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire. Higher values represent a worse outcome.

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

  4. Changes in Kessler-10 score

    Changes in Health Quality of Life measures along time assessed by using the questionnaire Kessler-10 (K10, numeric score). Higher values represent a worse outcome.

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

  5. Changes in Health Quality of Life measures along time using BCN-Q questionnaire

    Changes in Health Quality of Life measures along time using BCN-Q questionnaire (descriptive questionnaire).

    Time frame: timepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)

07

Study locations

5 of 5 sites recruiting
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • Zoran Stojanovic, MD, PhD · Contact
    • Cristina Prat, MD, PhD · Sub investigator
    • Zoran Stojanovic, MD, PhD · Principal investigator
  • Hospital Sant Joan de Déu
    Esplugues De Llobregat, Barcelona 08950, Spain
    Recruiting
    • Antoni Noguera, MD, PhD · Contact
    • Antoni Noguera, MD, PhD · Principal investigator
  • Hospital del Mar
    Barcelona, 08003, Spain
    Recruiting
    • Neus Jové, MD · Contact
    • Neus Jové, MD · Principal investigator
    • Francisca Sánchez, MD · Sub investigator
    • Marisol Domínguez, MD · Sub investigator
    • Núria López, MD · Sub investigator
  • Hospital Universitari Vall d'Hebron-Drassanes
    Barcelona, Spain
    Recruiting
    • Adrián Sánchez, MD, PhD · Contact
    • Adrián Sánchez, MD, PhD · Principal investigator
    • Malú De Souza, MD, PhD · Sub investigator
    • Jiménez, MD · Sub investigator
    • Pere Soler, MD, PhD · Principal investigator
    • Andrea Martín, MD · Sub investigator
    • Antoni Soriano, MD, PhD · Sub investigator
    • Teresa Tórtola, MD, PhD · Sub investigator
    • Israel Molina, MD, PhD · Sub investigator
    • Núria Saborit · Sub investigator
  • Servicios Clínicos de Barcelona
    Barcelona, Spain
    Recruiting
    • Joan Pau Millet · Contact
    • Joan Pau Millet, MD, PhD · Principal investigator
    • Xavier Casas, MD · Sub investigator
    • Israel Molina, MD · Sub investigator
    • Gónzalez-Díaz, MD · Sub investigator
    • Maldonado, MD · Sub investigator
    • Altet, MD · Sub investigator
    • Jaume Ollé-Goig, MD · Sub investigator
    • Núria Forcades, MD · Sub investigator
08

References and documents

Publications

  • Romero-Tamarit A, Valles X, Munar-Garcia M, Espinosa-Pereiro J, Saborit N, Tortola MT, Stojanovic Z, Roure S, Antuori A, Cardona PJ, Soriano-Arandes A, Martin-Nalda A, Espiau M, de Souza-Galvao ML, Jimenez MA, Noguera-Julian A, Molina I, Casas X, Dominguez-Alvarez M, Jove N, Gogichadze N, L Fonseca K, Arias L, Millet JP, Sanchez-Montalva A, Vilaplana C. A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings. Infection. 2024 Apr;52(2):611-623. doi: 10.1007/s15010-024-02184-2. Epub 2024 Feb 13. PubMed 38349459 ↗
  • Roure S, Valles X, Sopena N, Benitez RM, Reynaga EA, Bracke C, Loste C, Mateu L, Antuori A, Baena T, Portela G, Llussa J, Flamarich C, Soldevila L, Tenesa M, Perez R, Plasencia E, Bechini J, Pedro-Botet ML, Clotet B, Vilaplana C. Disseminated tuberculosis and diagnosis delay during the COVID-19 era in a Western European country: a case series analysis. Front Public Health. 2023 May 18;11:1175482. doi: 10.3389/fpubh.2023.1175482. eCollection 2023. Erratum In: Front Public Health. 2023 Jun 28;11:1236874. doi: 10.3389/fpubh.2023.1236874. PubMed 37275492 ↗
  • Pujol-Cruells A, Vilaplana C. Specific Interventions for Implementing a Patient-Centered Approach to TB Care in Low-Incidence Cities. Front Med (Lausanne). 2019 Nov 26;6:273. doi: 10.3389/fmed.2019.00273. eCollection 2019. PubMed 31850353 ↗

Individual participant data

Plan to share: Undecided — IPD that underlie results in a publication might be shared with other researchers

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.

Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 104 months is above that.

Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2017
First posted
Oct 2, 2018
StartActual
Apr 19, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03691883
Lead sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
Hospital Universitari Vall d'Hebron (Drassanes), Servicios Clínicos de Barcelona, Germans Trias i Pujol Hospital, Hospital Sant Joan de Deu, Hospital del Mar
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Apr 19, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 27, 2024

Study contacts

Cris Vilaplana, MD, PhD
Contact
cvilaplana@gmail.com
934978677
Laura Villegas
Contact
secretary.ute@gmail.com
+34934978681
Cris Vilaplana, MD, PhD
principal investigator · Fundació Institut Germans Trias i Pujol

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion